KR102210575B1 - 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물 - Google Patents

암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물 Download PDF

Info

Publication number
KR102210575B1
KR102210575B1 KR1020157010519A KR20157010519A KR102210575B1 KR 102210575 B1 KR102210575 B1 KR 102210575B1 KR 1020157010519 A KR1020157010519 A KR 1020157010519A KR 20157010519 A KR20157010519 A KR 20157010519A KR 102210575 B1 KR102210575 B1 KR 102210575B1
Authority
KR
South Korea
Prior art keywords
acid
limited
regorafenib
examples include
acetylsalicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157010519A
Other languages
English (en)
Korean (ko)
Other versions
KR20150060869A (ko
Inventor
올라프 베버
카를 지겔보이어
Original Assignee
바이엘 파마 악티엔게젤샤프트
바이엘 에이쥐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102210575(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 파마 악티엔게젤샤프트, 바이엘 에이쥐 filed Critical 바이엘 파마 악티엔게젤샤프트
Publication of KR20150060869A publication Critical patent/KR20150060869A/ko
Application granted granted Critical
Publication of KR102210575B1 publication Critical patent/KR102210575B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157010519A 2012-09-25 2013-09-23 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물 Active KR102210575B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852.6 2012-09-25
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (2)

Publication Number Publication Date
KR20150060869A KR20150060869A (ko) 2015-06-03
KR102210575B1 true KR102210575B1 (ko) 2021-02-02

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157010519A Active KR102210575B1 (ko) 2012-09-25 2013-09-23 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물

Country Status (29)

Country Link
US (1) US10898500B2 (enExample)
EP (1) EP2900269B1 (enExample)
JP (1) JP6294888B2 (enExample)
KR (1) KR102210575B1 (enExample)
CN (1) CN104994876A (enExample)
AU (1) AU2013322854B2 (enExample)
BR (1) BR112015006686B1 (enExample)
CA (1) CA2885688C (enExample)
CL (1) CL2015000744A1 (enExample)
CY (1) CY1120939T1 (enExample)
DK (1) DK2900269T3 (enExample)
EA (1) EA032023B1 (enExample)
ES (1) ES2687985T3 (enExample)
HK (1) HK1214169A1 (enExample)
HR (1) HRP20181462T1 (enExample)
HU (1) HUE039878T2 (enExample)
IL (1) IL237690B (enExample)
LT (1) LT2900269T (enExample)
MX (1) MX357035B (enExample)
MY (1) MY183969A (enExample)
NZ (1) NZ705860A (enExample)
PH (1) PH12015500587A1 (enExample)
PL (1) PL2900269T3 (enExample)
PT (1) PT2900269T (enExample)
RS (1) RS57875B1 (enExample)
SG (2) SG10201702356VA (enExample)
SI (1) SI2900269T1 (enExample)
WO (1) WO2014048881A1 (enExample)
ZA (1) ZA201502840B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (enExample) 2012-06-13 2015-07-17 Hoffmann La Roche
MA37940B1 (fr) 2012-09-25 2018-09-28 Hoffmann La Roche Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EP3590939A1 (en) 2014-03-26 2020-01-08 F. Hoffmann-La Roche AG Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CA2984585A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
MX2018002217A (es) 2015-09-24 2018-03-23 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de autotaxina (atx).
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
EP3474858B1 (en) * 2016-06-28 2021-08-18 Asamedic AS Two-component composition comprising acetylsalicylic acid
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
WO2018219807A1 (en) * 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002014A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
NZ544920A (en) * 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR20080074974A (ko) * 2005-11-10 2008-08-13 바이엘 헬스케어 아게 당뇨병성 신경병증을 치료하기 위한 디아릴 우레아
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Journal of Cancer, 129 p245-255,2011.*
Lancet, 378, p2081-87,2011.*

Also Published As

Publication number Publication date
HUE039878T2 (hu) 2019-02-28
US20150202214A1 (en) 2015-07-23
WO2014048881A1 (en) 2014-04-03
NZ705860A (en) 2018-07-27
SG11201501963RA (en) 2015-04-29
MX357035B (es) 2018-06-25
CY1120939T1 (el) 2019-12-11
EP2900269A1 (en) 2015-08-05
ES2687985T3 (es) 2018-10-30
AU2013322854A1 (en) 2015-04-02
IL237690B (en) 2019-07-31
HRP20181462T1 (hr) 2018-11-02
CN104994876A (zh) 2015-10-21
US10898500B2 (en) 2021-01-26
SI2900269T1 (sl) 2018-10-30
MX2015003728A (es) 2015-09-23
EA032023B1 (ru) 2019-03-29
JP6294888B2 (ja) 2018-03-14
DK2900269T3 (en) 2018-10-01
IL237690A0 (en) 2015-05-31
LT2900269T (lt) 2018-11-12
CA2885688A1 (en) 2014-04-03
AU2013322854B2 (en) 2018-07-19
BR112015006686A2 (pt) 2019-08-27
MY183969A (en) 2021-03-17
KR20150060869A (ko) 2015-06-03
RS57875B1 (sr) 2018-12-31
HK1214169A1 (zh) 2016-07-22
SG10201702356VA (en) 2017-04-27
EA201500365A1 (ru) 2015-08-31
PT2900269T (pt) 2018-10-22
ZA201502840B (en) 2017-11-29
PH12015500587A1 (en) 2015-05-11
BR112015006686B1 (pt) 2022-04-05
PL2900269T3 (pl) 2019-02-28
CA2885688C (en) 2021-03-02
JP2015529234A (ja) 2015-10-05
EP2900269B1 (en) 2018-08-01
CL2015000744A1 (es) 2016-01-08

Similar Documents

Publication Publication Date Title
KR102210575B1 (ko) 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물
AU2023282197B2 (en) Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
HK40015063A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150423

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180921

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200225

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201015

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200225

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201015

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200323

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180921

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20201127

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20201110

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201015

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200323

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180921

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210127

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210127

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241230

Start annual number: 5

End annual number: 5